Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 358 results for "adap"

Adaptimmune's TCR candidate shows encouraging activity in Phas...

News Editor Data from a 20-subject Phase 1/2 clinical trial assessing Adaptimmune's (ADAP -5.9%) T-cell receptor (TCR) therapeutic candidate, NY-ESO-1, in patients with multiple myeloma show an encouraging antitumor effect. The results were ... Seeking Alpha, 1 month ago
Securities Technology Monitor

Adaptimmune touts a promising snapshot of TCRs for myeloma

T-cell pioneer Carl June Adaptimmune ( $ADAP ) posted a promising early glimpse of its potential in the TCR cancer drug arena, an up-and-coming arm of the engineered T-cell programs now in the clinic. Investigators are reporting that out of 20 ...
 FierceBiotech1 month ago Adaptimmune's NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence, Clinical Activity and Tolerability in Clinical Study in Multiple Myeloma Patients  Consumer Electronics Net1 month ago Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAP...  CNN Money1 month ago Adaptimmune's IND Application for MAGE-A10 Accepted  Zacks.com1 month ago
[x]  
RTTNews.com

VRTX Drug Gets Approval, AGTC Surges On Biogen Deal, PFE Gets A Date With FDA

Adaptimmune Therapeutics plc (ADAP) is all set to initiate an open label phase I/II study of its wholly-owned MAGE-A10 T therapeutic candidate in patients with non-small cell lung cancer, following the acceptance of the company's investigational new ...
 RTTNews.com1 month ago

Adaptimmune: FDA Accepts IND For MAGE-A10 T - Quick Facts

Adaptimmune Therapeutics plc (ADAP) announced the U.S. FDA has accepted the company's investigational new drug application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 in patients with ...
 RTTNews.com1 month ago
AIDS Foundation Of Chicago

Declare ADAP an essential service ahead of government shutdown in IL

On July 1, Illinois state government will shut down if the General Assembly and Governor Bruce Rauner cannot come to an agreement on a budget. This could mean a grim future for people with HIV in Illinois, as programs like the AIDS Drug ...
 AIDS Foundation Of Chicago2 months ago Governor Rauner signs federal pass-through budget  AIDS Foundation Of Chicago1 week ago

Mid-Day Changers: Adaptimmune Therapeutics plc (ADAP), Chiasma, Inc (CHMA), B2Gold Corp. (BTG), NRG Yield, Inc. (NYLD-A), Egalet Corporation (EGLT)

WallStreet Scope July 31st, 2015: Mid Day Changers Adaptimmune Therapeutics plc ( ADAP ) of the Healthcare sector has changed by 3.38% and at noon is trading with a volume of 25,952 shares with a volatility this week of 9.68%. Adaptimmune ...
 WallStreetScope.com1 month ago Most Volatile Stocks: Adaptimmune Therapeutics plc (ADAP), Penn West Petroleum Ltd. (PWE), Enzon Pharmaceuticals Inc. (ENZN), Infosonics Corp. (IFON), Synthetic Biologics Inc. (SYN)  WallStreetScope.com1 month ago Most Volatile Stocks: Epizyme, Inc. (EPZM), Adaptimmune Therapeutics plc (ADAP), Datawatch Corporation (DWCH), VMware, Inc. (VMW), CytRx Corporation (CYTR)  WallStreetScope.com1 month ago WallStreet Morning Outlook: Intrepid Potash, Inc. (IPI), Rubicon Minerals Corporation (RBY), Adaptimmune Therapeutics plc (ADAP), Yulong Eco-Materials Limited (YECO), Silver Spring Networks, Inc. (SSNI)  WallStreetScope.com1 month ago

Private Insurance--and ADAP--Tied to Undetectable Viral Load in US Women

IAS 2015: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention Vancouver, Canada 18-22 July 2015 IAS 2015, July 19-22, 2015, Vancouver ......."using ADAP independently lowered risk of unsuppressed viral load in women with no ...
 National AIDS Treatment Advocacy Project1 month ago

European ADRs Gain as Tech Developers Edge Up

In the UK, microprocessor designer ARM ( ARMH ) rose by 3.8% while Adaptimmune Therapeutics ( ADAP ), a clinical-stage biopharmaceutical company, expanded by 2.3% and education and media company Pearson rose by 1.9% after announcing that it had ...
 Nasdaq1 month ago European ADRs Edge Up as Pharma Stocks Gain  Nasdaq1 month ago European ADRs Inch Down as Pharmaceutical Stocks Slide Lower  Nasdaq1 month ago European ADRs Gain Traction as Retail Stocks Surge  Nasdaq2 months ago

Analysts Set $22.00 Price Target for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) has received an average broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock ...
 SleekMoney1 month ago Zacks: Brokerages Set $22.00 Target Price for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)  WKRB News1 month ago Zacks: Adaptimmune Therapeutics PLC Receives Average Recommendation of Buy from Analysts (NASDAQ:ADAP)  Ticker Report1 month ago Adaptimmune Therapeutics PLC Receives Average Rating of Buy from Analysts (NASDAQ:ADAP)  SleekMoney1 month ago

Adaptimmune Therapeutics PLC -s Buy Rating Reiterated at Leerink Swann (ADAP)

Leerink Swann restated their buy rating on shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) in a report issued on Thursday, Market Beat reports. They currently have a $24.00 target price on the stock. ADAP has been the subject of a number of ...
 WKRB News1 month ago Adaptimmune Therapeutics PLC Given Buy Rating at Leerink Swann (ADAP)  Ticker Report1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less